Research analysts who have asked questions during IM Cannabis earnings calls.
Recent press releases and 8-K filings for IMCC.
IM Cannabis Raises Over US$2.1 Million Through Note Purchase Agreements
IMCC
Debt Issuance
Convertible Preferred Issuance
New Projects/Investments
- IM Cannabis Corp. (IMCC) secured US$2,171,660.40 in debt financing through two note purchase agreements with L.I.A. Pure Capital Ltd..
- The funds are intended to address liquidity requirements, repay approximately US$500,000 of existing creditors, and support general corporate purposes.
- The financing involves convertible notes issued on January 7, 2026, for US$1,538,749 and on January 20, 2026, for US$632,911.50, both carrying an 8% annual interest rate and an 18-month maturity.
- The notes are convertible into common shares at a variable price with a US$0.29 per share floor, and the company issued 228,150 warrants exercisable at C$3.45 per share.
- IMCC will file a Form F-3 registration statement to facilitate the resale of common shares issued upon conversion of these notes.
Jan 26, 2026, 10:12 PM
IM Cannabis Raises Debt Financing
IMCC
Debt Issuance
New Projects/Investments
- IM Cannabis Corp. has raised a total of US$2,171,660.40 in debt financings from an arm's length third party to manage its current liquidity requirements.
- The financing includes a First Note in the principal amount of US$1,538,749 issued on January 7, 2026, and a Second Note in the principal amount of US$632,911.50 issued on January 20, 2026.
- Both notes bear an interest rate of 8% per annum, increasing to 14% upon default, and have a maturity date of 18 months from their issuance.
- The notes are convertible into Common Shares, with the First Note having a fixed conversion price of US$1.47 (not lower than US$0.29) and the Second Note at US$1.38 (not lower than US$0.275).
- Approximately US$1,000,000 of the proceeds were used to repay certain existing creditors, with the remaining funds allocated to general corporate purposes, working capital, and strategic operational initiatives.
Jan 26, 2026, 9:53 PM
IM Cannabis Explores U.S. Market Entry and Engages Financial Advisors
IMCC
New Projects/Investments
M&A
- IM Cannabis Corp. (IMCC) is actively evaluating strategic opportunities to expand its operations into the United States cannabis market.
- This initiative follows President Donald Trump's executive order, signed on December 18, 2025, which directs the Attorney General to expedite the rescheduling of marijuana from Schedule I to Schedule III.
- IMCC has engaged SSC Advisors to provide financial advisory services for its U.S. market entry strategy and to assess potential divestitures of its German and Israeli operations.
Dec 30, 2025, 12:52 PM
IM Cannabis explores U.S. market entry and potential divestitures
IMCC
New Projects/Investments
M&A
- IM Cannabis Corp. (IMCC) is actively evaluating strategic opportunities to expand its operations into the U.S. cannabis market.
- This initiative follows President Donald Trump's executive order signed on December 18, 2025, which directs the Attorney General to expedite the rescheduling of marijuana from Schedule I to Schedule III.
- The Company has engaged SSC Advisors as financial advisors to assist with its U.S. entry strategy and assess potential divestitures of its current German and Israeli operations.
Dec 30, 2025, 12:42 PM
IM Cannabis Corp. Reports Q3 2025 Financial Results and Going Concern Warning
IMCC
Earnings
Profit Warning
Board Change
- IM Cannabis Corp. reported a net loss of $3.9 million for Q3 2025, compared to a net loss of $1.1 million in Q3 2024, with revenue for the quarter at $13.9 million, similar to the prior year period.
- The company's financial statements as of September 30, 2025, include a note regarding its ability to continue as a going concern, with projected cash flow for the remainder of 2025 indicating uncertainty.
- Cash and restricted cash on hand totaled $2.3 million as of September 30, 2025, an increase from $0.9 million on December 31, 2024.
- IM Cannabis Corp. has pivoted its focus and resources to the German medical cannabis market following April 2024 legalization, aiming for accelerated growth in the region.
- On July 11, 2025, the company announced the filing and effectiveness of a shelf registration statement (Form F-3), allowing it to offer and sell up to $50 million of its securities from time to time.
Nov 13, 2025, 2:16 PM
IM Cannabis Reports Q3 2025 Financial Results with Impairment and Going Concern Note
IMCC
Earnings
Profit Warning
- IM Cannabis Corp. reported consistent revenue of $13.9 million for Q3 2025 compared to Q3 2024, but its gross profit decreased by 13% to $2.7 million with a gross margin of 20%.
- The company posted a net loss of $3.9 million for Q3 2025, significantly higher than the $1.1 million net loss in Q3 2024, primarily due to a $3.1 million one-time goodwill and intangible asset impairment.
- Basic and diluted loss per share for Q3 2025 was $0.75, compared to a loss of $0.41 per share in Q3 2024.
- The financial statements as of September 30, 2025, include a note regarding the company's ability to continue as a going concern.
Nov 13, 2025, 2:00 PM
IM Cannabis Announces Board Changes and Strategic Review
IMCC
Board Change
New Projects/Investments
- IM Cannabis Corp. announced significant board changes, effective September 15, 2025, including the resignations of Shmulik Arbel and Brian Schinderle from the Board and its committees.
- Asaf Yitzhaik and Eli Zamir were appointed to the Board and Audit Committee, with Mr. Zamir also joining the Compensation Committee.
- Oz Adler was named the new Chairman of the Board, succeeding Oren Shuster, who will continue as Chief Executive Officer and a director.
- The company also decided to explore additional business activities to enhance long-term growth opportunities and create shareholder value.
Sep 16, 2025, 10:07 AM
Quarterly earnings call transcripts for IM Cannabis.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more